Drug Approval | June 13, 2026
UK approves Wegovy pill in major shift in obesity treatment options
Approval is based on results from the phase 3 OASIS 4 clinical trial
Approval is based on results from the phase 3 OASIS 4 clinical trial
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
The Danish biotech company confirmed the global study will begin in the second half of 2026
ICMR-led consultation calls for stricter HFSS regulations, nutrition literacy, and healthier food environments
The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
